Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
Xconomy
JANUARY 4, 2019
Topics ranged from the worries over CRISPR genome editing and Wild West biohacking, to Nobel Prize-fueled drug approvals and the headaches around drug prices (even for drugs meant to cure headaches). You can help with that by sending us frequent feedback via email (first initial-last name-at-xconomy.com) and Twitter.
69 
Let's personalize your content